### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL  OMB Number: 3235-02			
OMB Number:	3235-028		

37 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						Occilo	00(	, 01 1110	mvesam		ompany 7 tot	01 10-10								
1. Name and Address of Reporting Person*  KINGSLEY ALFRED D					2. Issuer Name <b>and</b> Ticker or Trading Symbol BIOTIME INC [ BTX ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner						
(Last) (First) (Middle) 150 E. 57TH STREET				oate of 06/20		est Trai	nsaction (I	Mont	h/Day/Year)		X Officer (give title below) Other (specification)  See Remarks									
(Street)  NEW Y	DRK NY 10022			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(Si	ate) (	(Zip)										Person							
		Tab	le I - No	on-Deriv	vative	Sec	uriti	es A	cquired	l, Di	sposed (	of, or Be	nefic	ially	Owned	ł				
Da			Date	. Transaction late Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed (		ies Acquired (A) or Of (D) (Instr. 3, 4 and 5		nd 5)	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D) Pri		•	Transaction(s) (Instr. 3 and 4)					
Common	Shares, no	par value		11/06/	/2015	2015		S		100,000	) <sup>(1)</sup> D	\$3.	.83	5,938,055(2)		D				
Common	Shares, no	par value													1,506,905		I	By Greenbelt Corp.		
Common Shares, no par value													375,351			I	By Greenway Partners, LP			
		Т	able II								posed of converti				wned					
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date Execution if any (Month/Day/Year)		ned n Date,	4. Transacti Code (Ins		5. Number 6		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		nt 8.	Price of erivative ecurity 1str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amour or Number of Shares	er						
Option to Purchase Common Shares	\$3.57								(3)		06/30/2020	Common Shares	50,00	00		50,00	0	D		
Option to Purchase Common Shares	\$3.11								(4)		06/30/2019	Common Shares	50,00	00		50,000		D		
Option to Purchase Common Shares	\$4.13								(5)		06/30/2018	Common Shares	50,00	00		50,00	00	D		
Option to Purchase Common Shares	\$4.6								(6)		06/30/2017	Common Shares	50,00	00		50,000		D		
Option to Purchase Common Shares	\$5.13								(7)		06/30/2016	Common Shares	50,00	00		50,00	00	D		

#### **Explanation of Responses:**

- 1. The securities were sold in a private transaction. Mr. Kingsley plans to invest the sale proceeds in Ascendance Biotechnology, Inc., a new subsidiary of BioTime.
- 2. Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
- 3. 12,500 options became exercisable on September 30, 2015 and the remaining 37,500 options will become exercisable in 3 equal quarterly installments based upon continued service on the board of directors.
- $4.\ 12{,}500\ options\ became\ exercisable\ on\ September\ 30{,}\ 2014;\ December\ 31{,}\ 2014;\ March\ 31{,}\ 2015;\ and\ June\ 30{,}\ 2015.$
- 5. 12,500 options became exercisable on September 30, 2013; December 31, 2013; March 31, 2014; and June 30, 2014.
- 6. 12,500 options became exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013.
- 7. 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

## Remarks:

Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.

/s/ Alfred D. Kingsley

11/10/2015

\*\* Signature of Reporting Person

Doto

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.